Search

Andrew W. Sutton

Examiner (ID: 2699, Phone: (571)272-6093 , Office: P/3765 )

Most Active Art Unit
3765
Art Unit(s)
3765, 3732
Total Applications
970
Issued Applications
523
Pending Applications
21
Abandoned Applications
428

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17140082 [patent_doc_number] => 20210308093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => ACTIVATOR FOR SIMULTANEOUSLY ACTIVATING OXIDATIVE PHOSPHORYLATION AND INHIBITING GLYCOLYSIS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/261430 [patent_app_country] => US [patent_app_date] => 2020-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2944 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17261430 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/261430
ACTIVATOR FOR SIMULTANEOUSLY ACTIVATING OXIDATIVE PHOSPHORYLATION AND INHIBITING GLYCOLYSIS AND USE THEREOF Jun 27, 2020 Abandoned
Array ( [id] => 18057899 [patent_doc_number] => 20220388985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY [patent_app_type] => utility [patent_app_number] => 17/619459 [patent_app_country] => US [patent_app_date] => 2020-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17640 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 1249 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17619459 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/619459
TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY Jun 17, 2020 Abandoned
Array ( [id] => 17896975 [patent_doc_number] => 20220306637 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => Imidazopyrazine Derivatives and the Use Thereof as Medicament [patent_app_type] => utility [patent_app_number] => 17/616205 [patent_app_country] => US [patent_app_date] => 2020-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5825 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616205 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/616205
Imidazopyrazine derivatives and the use thereof as medicament Jun 2, 2020 Issued
Array ( [id] => 17355280 [patent_doc_number] => 20220016076 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN [patent_app_type] => utility [patent_app_number] => 16/890722 [patent_app_country] => US [patent_app_date] => 2020-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19088 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16890722 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/890722
SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN Jun 1, 2020 Abandoned
Array ( [id] => 17720380 [patent_doc_number] => 20220213100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/614652 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37345 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614652 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/614652
Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers May 28, 2020 Issued
Array ( [id] => 17761393 [patent_doc_number] => 20220235005 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => FUNGICIDAL N-(PYRID-3-YL)CARBOXAMIDES [patent_app_type] => utility [patent_app_number] => 17/608497 [patent_app_country] => US [patent_app_date] => 2020-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45973 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 1599 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17608497 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/608497
FUNGICIDAL N-(PYRID-3-YL)CARBOXAMIDES May 25, 2020 Abandoned
Array ( [id] => 17945682 [patent_doc_number] => 20220332699 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => COMPOUNDS, COMPOSITIONS, AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/613870 [patent_app_country] => US [patent_app_date] => 2020-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59712 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17613870 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/613870
COMPOUNDS, COMPOSITIONS, AND METHODS OF USE May 23, 2020 Pending
Array ( [id] => 17749531 [patent_doc_number] => 20220227735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => THERAPEUTIC METHODS AND COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/605732 [patent_app_country] => US [patent_app_date] => 2020-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20473 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605732 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/605732
THERAPEUTIC METHODS AND COMPOUNDS Apr 21, 2020 Pending
Array ( [id] => 17719009 [patent_doc_number] => 20220211728 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => ALKYL-TPP COMPOUNDS FOR MITOCHONDRIA TARGETING AND ANTI-CANCER TREATMENTS [patent_app_type] => utility [patent_app_number] => 17/604651 [patent_app_country] => US [patent_app_date] => 2020-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9654 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17604651 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/604651
ALKYL-TPP COMPOUNDS FOR MITOCHONDRIA TARGETING AND ANTI-CANCER TREATMENTS Apr 15, 2020 Pending
Array ( [id] => 17656960 [patent_doc_number] => 20220177425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => SMALL MOLECULES FOR CANCER THERAPY THAT REDUCE THE EXPRESSION OF TRANSCRIPTION FACTORS KLF5 AND EGR-1 [patent_app_type] => utility [patent_app_number] => 17/602924 [patent_app_country] => US [patent_app_date] => 2020-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12786 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 183 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602924 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/602924
Small molecules for cancer therapy that reduce the expression of transcription factors KLF5 and EGR-1 Apr 9, 2020 Issued
Array ( [id] => 17596918 [patent_doc_number] => 20220146492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => CELL MEMBRANE PERMEABILITY RESTORING THERAPY [patent_app_type] => utility [patent_app_number] => 17/602136 [patent_app_country] => US [patent_app_date] => 2020-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31329 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602136 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/602136
CELL MEMBRANE PERMEABILITY RESTORING THERAPY Apr 9, 2020 Pending
Array ( [id] => 17702768 [patent_doc_number] => 20220202774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SPINAL CORD INJURY OR SPINAL STENOSIS [patent_app_type] => utility [patent_app_number] => 17/594889 [patent_app_country] => US [patent_app_date] => 2020-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594889 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/594889
PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SPINAL CORD INJURY OR SPINAL STENOSIS Apr 6, 2020 Abandoned
Array ( [id] => 17685728 [patent_doc_number] => 20220193020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => Pharmaceutical Composition Comprising Trimebutine or Pharmaceutically Acceptable Salt Thereof as an Active Ingredient For Prevention or Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 17/600976 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8105 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17600976 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/600976
Pharmaceutical composition comprising trimebutine or pharmaceutically acceptable salt thereof as an active ingredient for prevention or treatment of cancer Apr 5, 2020 Issued
Array ( [id] => 17609765 [patent_doc_number] => 20220152044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => TREATMENT OF INFLAMMATORY DISEASES OF THE CENTRAL NERVOUS SYSTEM [patent_app_type] => utility [patent_app_number] => 17/593249 [patent_app_country] => US [patent_app_date] => 2020-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9926 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17593249 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/593249
TREATMENT OF INFLAMMATORY DISEASES OF THE CENTRAL NERVOUS SYSTEM Mar 15, 2020 Pending
Array ( [id] => 20187036 [patent_doc_number] => 12398141 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-26 [patent_title] => JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine [patent_app_type] => utility [patent_app_number] => 17/437944 [patent_app_country] => US [patent_app_date] => 2020-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28684 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 299 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17437944 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/437944
JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine Mar 10, 2020 Issued
Array ( [id] => 20372394 [patent_doc_number] => 12479816 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => 20-HETE formation inhibitors [patent_app_type] => utility [patent_app_number] => 17/429289 [patent_app_country] => US [patent_app_date] => 2020-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54463 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429289 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/429289
20-HETE formation inhibitors Feb 6, 2020 Issued
Array ( [id] => 18165640 [patent_doc_number] => 20230032239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => A METHOD OF TREATMENT IN PREDISPOSED SUBJECTS FOR LMNA-RELATED DILATED CARDIOMYOPATHY [patent_app_type] => utility [patent_app_number] => 17/791110 [patent_app_country] => US [patent_app_date] => 2020-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7610 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791110 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/791110
A METHOD OF TREATMENT IN PREDISPOSED SUBJECTS FOR LMNA-RELATED DILATED CARDIOMYOPATHY Jan 14, 2020 Pending
Array ( [id] => 17428344 [patent_doc_number] => 20220056052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/415584 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25540 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 469 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17415584 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/415584
QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS Dec 26, 2019 Pending
Array ( [id] => 17443654 [patent_doc_number] => 20220064159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => BICYCLIC DERIVATIVES [patent_app_type] => utility [patent_app_number] => 17/415309 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18660 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 1677 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17415309 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/415309
BICYCLIC DERIVATIVES Dec 12, 2019 Abandoned
Array ( [id] => 19042281 [patent_doc_number] => 11931354 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-19 [patent_title] => Formulations of oxabicycloheptanes and oxabicycloheptenes [patent_app_type] => utility [patent_app_number] => 16/705699 [patent_app_country] => US [patent_app_date] => 2019-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11534 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16705699 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/705699
Formulations of oxabicycloheptanes and oxabicycloheptenes Dec 5, 2019 Issued
Menu